Adakveo Generic Name & Formulations
Crizanlizumab-tmca 10mg/mL; per vial; soln for IV infusion after dilution; preservative-free.
Single-dose vial (10mL)—1
To reduce the frequency of vaso-occlusive crises (VOCs) in sickle cell disease.
Adakveo Dosage and Administration
Give by IV infusion over 30mins. ≥16yrs: 5mg/kg at Week 0, Week 2, and every 4 weeks thereafter.
<16yrs: not established.
Adakveo Boxed Warnings
Monitor for infusion-related reactions. Discontinue if severe infusion-related reactions occur; treat appropriately. Interrupt or slow infusion rate if mild to moderate infusion-related reactions occur; treat symptomatically. Consider premedication and/or reduced infusion rate for subsequent infusions. Pregnancy. Nursing mothers.
Caution with corticosteroids, unless indicated (eg, treating anaphylaxis). Interferes with automated platelet counts (esp. when collected in tubes containing EDTA) that may lead to unevaluable or falsely decreased platelet counts; run tests within 4hrs of collection or collect in citrate tubes instead.
Adakveo Adverse Reactions
Nausea, arthralgia, back pain, abdominal pain, pyrexia; infusion-related reactions.
Adakveo Clinical Trials
Adakveo Patient Counseling